Literature DB >> 12915591

The myth of measurable disease in ovarian cancer.

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12915591     DOI： 10.1200/JCO.2003.08.148

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

Authors:  Shawna L Bull Phelps; Juliet Carbon; Andrew Miller; Emely Castro-Rivera; Shanna Arnold; Rolf A Brekken; Jayanthi S Lea
Journal:  Am J Obstet Gynecol       Date:  2008-11-06       Impact factor: 8.661

Review 2.  Pharmaceutical management of ovarian cancer : current status.

Authors:  Maurie Markman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

4.  Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.

Authors:  Devansu Tewari; Bradley J Monk; Mark Hunter; Camille A Falkner; Robert A Burger
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

Review 5.  Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.

Authors:  Charlotte S Marcus; G Larry Maxwell; Kathleen M Darcy; Chad A Hamilton; William P McGuire
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.